On July 18, the official website of the State Drug Administration revealed that the oral antiviral drug malselenosavir tablets were approved for marketing to treat previously healthy adult patients with simple influenza A and B, excluding patients at high risk of influenza-related complications. Maseloxavir is a new generation polymerase acid protein endonuclease inhibitor independently developed by Zhengxiang Pharmaceutical. It has broad-spectrum anti-influenza virus properties, and has antiviral activity against influenza A and B influenza viruses, and highly lethal avian influenza viruses.

On July 18, the official website of the State Drug Administration revealed that the oral antiviral drug malselenosavir tablets were approved for marketing to treat previously healthy adult patients with simple influenza A and B, excluding patients at high risk of influenza-related complications. Maseloxavir is a new generation polymerase acid protein endonuclease inhibitor independently developed by Zhengxiang Pharmaceutical. It has broad-spectrum anti-influenza virus properties, and has antiviral activity against influenza A and B influenza viruses, and highly lethal avian influenza viruses.